The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections, used in combination with metronidazole, and for complicated urinary tract infections.
Compared to placebo, treatment with ustekinumab resulted in a significantly greater proportion of adults with moderate to severe UC achieving clinical remission at week 44 (primary endpoint).
Guidelines address diagnosis, treatment, and overall clinical management of adult patients
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to seladelpar (CymaBay Therapeutics) for the treatment of early-stage primary biliary cholangitis (PBC).
The Food and Drug Administration (FDA) has granted Fast Track designation to RDD-0315, a novel topical gel for the treatment of fecal incontinence in spinal cord injury patients.
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
Among the HCC patients included in the analysis, 14.9% (N=2293) were recorded as having used a statin after diagnosis.
For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.
To examine the impact of antiplatelet use on hepatic fibrosis progression, study authors conducted a systematic review and meta-analysis using studies identified through a search of Medline, EMBASE, and PubMed from inception to October 2018.
Fresenius Kabi announced the availability of Omegaven (fish oil triglycerides) injectable emulsion as a source of calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis.
